—How It Works
"Our drug modulates existing cellular machinery rather than forcing synthetic pathways”
The mechanism of action for RLC/929 highlights a sophisticated approach to cellular regulation. By targeting Protein Kinase C (PKC), our drug leverages a central signaling node to achieve diverse therapeutic outcomes.
Mechanism of Action Breakdown
- PKC Activation: Acts as the trigger for intracellular signaling cascades.
- Cellular Differentiation: Forces abnormal or undifferentiated cells back into their functional, normal states.
- Cytokine Regulation: Modulates the immune response to promote balance.
- Aquaporin Regulation: Controls cellular water channels to maintain fluid homeostasis and barrier integrity.
Strategic Clinical Advantages
- Targeted Resilience: Modulates existing cellular machinery rather than forcing synthetic pathways.
- Multisystem Efficacy: Addresses structural (differentiation), immunological (cytokines), and physiological (aquaporins) defects simultaneously.
How does our drug bind to cells?
RLC/929 begins working at the cellular level by binding to the C1 region of Protein Kinase C (PKC), PKC being a key enzyme that helps control how cells communicate, grow, and react to their environment. PKC acts like a "molecular switchboard" inside human cells, helping translate signals at the cell membrane into instructions that can influence repair through differentiation, promote cell survival, and return cells to normal function.
Once PKC is activated a number of repair activities are initiated
How does activating PKC repair cells?
How does our drug clear inflammation?